The global plasma protein therapeutics market was approximately about USD24.94 billion in 2021 and is projected to rise to around USD 41.75 billion by 2028, with a compound annual growth rate (CAGR) of around 6.7% throughout the forecast period.
The global plasma protein therapeutics market was approximately about USD24.94 billion in 2021 and is projected to rise to around USD 41.75 billion by 2028, with a compound annual growth rate (CAGR) of around 6.7% throughout the forecast period. The study examines the drivers, constraints, and challenges in the plasma protein therapeutics market, as well as their impact on demand throughout the forecast period. In addition, the research looks at the market for plasma protein therapeutics and new potential.
Plasma Protein Therapeutics Market: Overview
Plasma protein therapeutics is a type of biological therapy that uses plasma, a biological substance with a distinct biochemical profile that may be produced in a variety of ways. Plasma, which contains proteins, antibodies, salts, enzymes, and water, is the most abundant component in human blood. Platelets, white blood cells, and red blood cells are all excluded from plasma, which is the liquid component of blood. Plasma performs a variety of important transport tasks. Various chronic, life-threatening, uncommon, and hereditary disorders are treated with plasma protein therapeutics. They're utilized to treat immunological and autoimmune deficiencies, as well as bleeding and neurological diseases, as well as burns and shocks.
The global market is projected to be significantly impacted by the COVID-19 pandemic. In the case of COVID-19, many biotech & pharmaceutical companies, research institutes, and government organizations in various countries are focusing on effective and rapid technologies for the rapid diagnosis of COVID-19, as well as creating vaccines and novel therapeutics to combat the situation. COVID-19 has a direct influence on production & demand, as well as market disruption and supply chain, with financial implications for businesses and financial markets. The outbreak of COVID-19 across the globe has in the short term ceased plasma donation, impacting the market for plasma protein therapeutics. Nevertheless, researchers are concentrating their efforts on plasma-based treatments to see if they might help cure the COVID-19 virus. This is likely to boost the market during the forecast period.
Plasma Protein Therapeutics Market: Growth Drivers
Growing incidences of chronic diseases to foster the market growth
The market is being primarily driven by the increasing incidence of over 200 life-threatening disorders that affect the neurological and immune systems, including idiopathic thrombocytopenic purpura, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and other infectious diseases such as varicella, tetanus, rabies, and hepatitis A & B. For instance, in the United States, the prevalence rate of idiopathic thrombocytopenic purpura (ITP) in individuals is around 66 incidences per 1,000,000 annually. Also, according to an epidemiological study on ITP in China, the annual incidence of ITP is 9.5 per 100,000, with adult females having a higher incidence than adult males (2:1), which might be connected to the fact that adult women are more prone to suffer autoimmune system illnesses. Further, the global plasma protein therapeutics market is boosted due to technological developments in reliable and cost-effective processes for separating proteins from plasma. Additionally, factors such as an increase in drug discovery & development programs, growing investment in R&D activities, and an increase in the number of clinical trials are propelling the market growth.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Plasma Protein Therapeutics Market: Restraints
Strict regulations in different countries to impede the market growth
Plasma collection standards in developing nations do not meet the fractionator's requirements. These countries have stringent laws and regulations in place to ensure the quality of their operations, beginning with the quality of the raw materials. Plasma fractionators are built specifically for it. In Europe, for example, the plasma pool for fractionation must be screened for hepatitis A, B, & C, HIV, as well as Parvovirus B. Many facilities which collect the blood are unable to meet those requirements, resulting in some retrieved plasma being wasted. Additionally, each stage of the plasma protein therapy lifecycle is affected by the quality and regulatory norms, including donor compliance, quality, safety, pharmacovigilance, therapy safety & efficacy, and the biological license application process. All such factors may hinder market growth.
Plasma Protein Therapeutics Market: Opportunities
High demand for Immunoglobulins (IG) to propel the market growth during the forecast period.
The number of medical indications for IG has been growing in recent years. Beyond primary immunodeficiency, IG has become a key therapy option for a variety of clinical reasons, including acute inflammatory and autoimmune diseases. Off-label prescription has also spread to nearly every medical profession. Demand for IG is rising as a result of off-label use in various applications, notably for the treatment of immunological deficiencies and neurological disorders. IG produced from plasma is used to treat a variety of inflammatory and autoimmune illnesses. Increased awareness and treatment of immunological weaknesses in developing countries has increased global demand for immunoglobulin. Clinical demand for these drugs has risen in recent years, and this trend is projected to continue as diagnostic technology improves and life expectancy rises thereby generating ample opportunities for the global plasma protein therapeutics market growth during the forecast period.
Plasma Protein Therapeutics Market: Challenges.
Unfavorable reimbursement policies to pose major challenge to market growth
Budgets for health care are under increasing strain. Plasma protein treatments have been dragged into the terrain of Health Technology Assessments (HTA), including the prospective use of cost-utility analysis (CUA) in the allocation of reimbursement funds, owing to funding through reimbursement channels from commercial and public payers. Given the high cost of medicines and the young nature of many indications, the use of these health economics methods may limit the availability of medications for patients in true need. This may serve as a major challenge to the growth of the market.
Plasma Protein Therapeutics Market: Segmentation
The global plasma protein therapeutics market is categorized into product type, application, and region. Based on the product type, the global market is classified into coagulation factors, immunoglobulin, albumins, c1 esterase inhibitors, and others. The application segment is divided into idiopathic thrombocytopenic, secondary immunodeficiency, primary immunodeficiency disorder, hemophilia, hereditary angioedema, and others.
Plasma Protein Therapeutics Market: Regional Landscape
North America to lead the market during the forecast period
North America is likely to lead the global plasma protein therapeutics market during the projected period. Factors such as the rising incidence and prevalence of neurological & autoimmune diseases are driving market expansion. The United States is likely to be the region's largest market. The region's growing geriatric population further expands the patient pool, as the aged people are more susceptible to neurological diseases. Furthermore, favorable government programs, rising blood donor awareness, the availability of improved protein fractioning processes, higher per capita income, and a spike in the proportion of research collaborations are all projected to boost market expansion in this region. On the other hand, Asia Pacific is estimated to grow at the fastest CAGR value owing to factors such as growing demand for advanced & effective options of treatment and developing healthcare infrastructure.
Plasma Protein Therapeutics Market: Competitive Landscape
The major players that are successfully operating in the global plasma protein therapeutics market are Biotest AG, CSL Behring, Grifols SA, Octapharma USA Inc., Takeda Pharmaceutical Company Ltd, Bio Products Laboratory, Shire PLC, Kedrion SpA, China Biologic Products Holdings Inc., and Baxter, among others.
Global plasma protein therapeutics market is segmented as follows:
By Product Type
Plasma is the single largest component made up of 90% of water and has enzymes, salts, antibodies, and other proteins. It can be defined as the clear, straw-colored fluid part of the blood which residue after red platelets, blood cells, white blood cells, and other cellular components are eliminated. Plasma proteins have different functions, including transport of different biochemicals (lipids, hormones, etc.) in the circulatory system; some functions of the plasma protein include blood clotting, fighting against diseases, and other vital functions. Various proteins are present in the plasma of human blood. A blend of simple proteins, lipoproteins, glycoproteins, and other additional conjugated proteins are called as plasma proteins. Plasma protein therapy is an inimitable biological medicine; it has a biochemical profile because of which it differs in processing and production methods and thus is used for the treatment of various genetic, life-threatening chronic and rare diseases.
According to the Plasma Protein Therapeutics Association (PPTA), plasma proteins are used in a variety of rare diseases treatment such as primary immunodeficiency disease, alpha-1 antitrypsin deficiency, and hemophilia A. It can also be used to treat conditions such as shocks & burns, Rh incompatibility, organ transplants, pediatric HIV, trauma, cardiopulmonary issues, liver conditions, and animal bites; they are also used in major surgeries. Hemophilia disease occurs in about 1 of every 5,000 male births, at present about 20,000 males in the U.S are living with the disorder. These plasma proteins play a vital function in clotting and providing immunity against the diseases.
The major driver for the plasma protein therapeutic market is the growing application of the plasma proteins derivative medicines. Development of novel plasma-derived therapies is another major driver for the growth of this market. Rising prevalence of life-threatening diseases including immune or neurological system such as chronic inflammatory demyelinating polyneuropathy (CIPD), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), and other infectious diseases are expected to drive the plasma protein therapeutic market growth. Additionally, modernization in the technologies provided efficient and cost-effective methods for fractionating the proteins from plasma, which is expected to boost the market growth. Implementation of stringent regulatory policies and issues pertaining to reimbursements are likely to inhibit the market’s trajectory. The existing complexity in biologics manufacturing is also expected to create threats for the market.
Based on product type, the plasma protein therapeutic market has been segmented into coagulation factors, immunoglobulin, alpha-1 proteinase inhibitor, and albumin. Based on application, the plasma protein therapeutic market can be divided into hemophilia, primary immunodeficiency disorder, idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and other indications (Kawasaki disease, GBS, CIDP). Growing government initiatives, increased awareness among the healthcare practitioners, and growing disposable income of the patients are some of the factors that drive the global market for plasma protein therapeutic.
According to the Plasma Protein Therapy Association (PPTA), North America region gained up to 40% of the market in 2013 and is expected to dominate the plasma protein therapeutic market with the highest amount of blood collection. Europe is the second largest market in the global plasma protein therapeutics market. Due to the increasing awareness about blood donations, Asia Pacific is expected to witness a noteworthy growth for the forecast period. Some of the most lucrative markets for plasma protein therapeutics in Europe include Switzerland, Germany, Spain, Italy, France, Sweden, and the U.K.
Some of the key players in plasma protein therapeutic market include Octapharma, CSL Limited, Baxter, Telecris, Grifols, LFB Group, Kedrion, and Chengdu Inst; Japan Red Cross, Shanghai Blood Institute, BPL Group, and Sanquin are some of the nonprofit organizations which are playing an important role in plasma protein therapeutic market.
The market is being primarily driven by the increasing incidence of over 200 life-threatening disorders that affect the neurological and immune systems, including idiopathic thrombocytopenic purpura, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and other infectious diseases such as varicella, tetanus, rabies, and hepatitis A&B. Additionally, factors such as an increase in drug discovery & development programs, growing investment in R&D activities, and increase in the number of clinical trials are propelling the market growth.
According to the Zion Market Research report, the global plasma protein therapeutics market was worth about 24.94 (USD billion) in 2021 and is predicted to grow to around 41.75 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 6.8 percent.
North America is likely to lead the global plasma protein therapeutics market during the projected period. Factors such as the rising incidence and prevalence of neurological and autoimmune diseases are driving market expansion. The United States is likely to be the region's largest market. The region's growing geriatric population further expands the patient pool, as the aged people are more susceptible to neurological diseases.